Medical weight management that goes beyond the prescription. Dr. Lindsey Bailey, DO combines GLP-1 therapy with comprehensive metabolic testing to address the root causes of weight gain — delivering results that last.
If you've tried diet after diet and the weight keeps coming back, it's not a willpower problem. It's a biology problem. Weight gain and resistance to weight loss are almost always driven by underlying metabolic dysfunction that no amount of calorie counting can fix.
Dr. Bailey runs comprehensive diagnostics to identify exactly which factors are working against you — then builds a protocol that addresses them directly, with GLP-1 therapy as one powerful tool in a broader metabolic strategy.
Average body weight reduction with semaglutide in clinical trials
Reduction in major cardiovascular events in high-risk patients
Of patients achieve >15% weight loss with tirzepatide
Approved for chronic weight management in adults with obesity or overweight + comorbidity
Clinical trial results. Individual results vary. GLP-1 therapy is most effective when combined with comprehensive metabolic evaluation and lifestyle support.
GLP-1 therapy is powerful — but it works best as part of a comprehensive metabolic strategy, not as a standalone prescription.
A thorough evaluation of all metabolic drivers — fasting insulin, HOMA-IR, advanced lipid panel, inflammatory markers, full thyroid cascade, sex hormones, and cortisol. Most weight loss programs skip the diagnostics entirely.
Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are the most clinically significant advances in weight management in decades. Dr. Bailey prescribes and manages GLP-1 therapy as part of a comprehensive metabolic protocol — not as a standalone prescription.
Thyroid dysfunction, low testosterone, and estrogen dominance all directly impair fat metabolism. Correcting these imbalances is often the missing piece that allows sustainable weight loss to finally occur.
Insulin resistance is the most common — and most overlooked — driver of weight gain. Dr. Bailey uses advanced testing to identify and reverse insulin resistance through targeted dietary, lifestyle, and pharmaceutical interventions.
Evidence-based nutrition guidance tailored to your metabolic profile, food preferences, and lifestyle. Not a generic diet plan — a protocol designed around your specific biology and the root causes identified in your labs.
Weight management is not a one-time prescription. Dr. Bailey monitors your progress, adjusts protocols based on response, and manages any side effects — providing the medical oversight that makes long-term success possible.
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications that mimic a naturally occurring gut hormone. They work by slowing gastric emptying, reducing appetite signals in the brain, improving insulin sensitivity, and promoting fat utilization. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most widely used GLP-1 medications and have demonstrated significant and sustained weight loss in clinical trials.
Yes. Dr. Bailey prescribes and manages GLP-1 therapy for patients throughout Colorado, Arizona, and Nebraska via telemedicine. Lab work is ordered to a local draw site near you, and all consultations are conducted via secure video.
GLP-1 medications are FDA-approved for adults with a BMI ≥30, or BMI ≥27 with at least one weight-related health condition (such as type 2 diabetes, high blood pressure, or high cholesterol). Candidacy also depends on your medical history, current medications, and metabolic profile. Dr. Bailey evaluates all of these factors during your initial consultation.
Ozempic and Wegovy both contain semaglutide — Ozempic is FDA-approved for type 2 diabetes, while Wegovy is approved specifically for weight management at a higher dose. Mounjaro and Zepbound both contain tirzepatide, which acts on both GLP-1 and GIP receptors (a dual agonist), and has shown even greater weight loss in trials than semaglutide alone. Dr. Bailey will recommend the most appropriate medication based on your clinical profile.
Research shows that weight regain is common after stopping GLP-1 medications without addressing the underlying metabolic drivers. This is why Dr. Bailey's approach combines GLP-1 therapy with comprehensive metabolic optimization — correcting hormone imbalances, insulin resistance, and lifestyle factors — to build a foundation that supports long-term weight maintenance.
Coverage varies significantly by plan. Ozempic is more commonly covered for patients with type 2 diabetes. Wegovy and Zepbound coverage for weight management is improving but remains inconsistent. Dr. Bailey's team can help you navigate prior authorization and identify manufacturer savings programs that can significantly reduce out-of-pocket costs.
The information on this page is for educational purposes only and does not constitute medical advice. GLP-1 medications require a prescription and medical supervision. Candidacy, dosing, and management must be determined by a licensed physician based on your individual health history and clinical evaluation. Always consult a qualified healthcare provider before starting any weight management program.
Book a free 15-minute Discovery Call with Dr. Bailey. She'll review your history, explain what's been working against you, and outline exactly how a comprehensive metabolic approach — including GLP-1 therapy if appropriate — can help.
Fort Collins, CO · Telemedicine across Colorado, Arizona & Nebraska